margin. Gleason grade at the PSM was an independent predictor of BCR compared to presence of PSM alone. In patients with Gleason sum 7 disease on traditional final pathology, those with Gleason 3 at the PSM had a lower BCR rate (25.0%, 8/32) compared to those with Gleason 4+ (58.8%, 10/17, p ¼ 0.02).
INTRODUCTION AND OBJECTIVES: Tumor volume measured on radical prostatectomy (RP) specimen has been shown to be associated with adverse pathologic and oncologic outcomes; however, it is difficult to calculate and cannot contribute to preoperative decision making. Advances in imaging technology may facilitate the prediction of prostate cancer outcomes prior to surgery. In this study, we evaluated the predictive value of the index tumor volume (ITV) calculated from prostate MRI in analyzing adverse pathologic outcomes following RP in a higher risk cohort.
METHODS: Clinical and pathologic data from a prospectively maintained, single-institution database were analyzed for patients who underwent 3T MRI prior to RP (without prior therapy) between 2007 and 2016, with an index tumor defined as a T2-visible lesion with the longest diameter. ITV was calculated from T2W MRI by multiplying length by width by depth by 0.52 to generate the volume of an ellipse. Adverse pathologic outcomes were determined on whole mount RP specimens, and defined as positive margins (PM), extracapsular extension (ECE), positive lymph nodes (LNI), and seminal vesicle invasion (SVI). Logistic regression was used to assess associations of clinical, imaging, and histopathological variables with adverse pathologic features. Receiver operating characteristic curves were used to characterize and compare ITV performance with Partin tables.
RESULTS: In our study period, 464 patients met our inclusion criteria. In our cohort, median age and PSA were 60 years (IQR 10) and 6.21 ng/ml (IQR 6), and 24.4% were 00 high risk 00 (Gleason 8-10) on biopsy . 15.6% of patients had PM, 23.5% ECE, 6.3% LNI, and 6.5% SVI. Patients with adverse outcomes were found to have larger median ITV (PM: 1.236cc vs 0.832cc, p¼0.045; ECE: 1.388cc vs 0.771cc, p<0.001; LNI: 2.750cc vs 0.801cc, p<0.001; SVI: 2.269cc vs 0.806cc, p<0.001). On multivariate analysis, ITV was found to be an independent predictor of ECE (OR: 1.211, p¼0.005), LNI (OR: 1.366, p<0.001), and SVI (OR: 1.305, p¼0.002), but not PM (OR: 1.052, p¼0.300). ITV alone and ITV+PSA were found to have predictive ability comparable to that of Partin tables (ECE: ITV AUC : 0.660 vs. ITV+PSA AUC :0.721 vs. Partin AUC : 0.717, LNI: ITV AUC : 0.802 vs. ITV+PSA AUC :0.881 vs. Partin AUC : 0.873, SVI: ITV AUC : 0.749 vs. ITV+PSA AUC :0.762 vs. Partin AUC : 0.806).
CONCLUSIONS: We demonstrate that Index Tumor Volume measured on T2W MRI is an independent predictor of ECE, LNI, and SVI following RP. We believe this easily calculated preoperative marker provides additional prognostic information, particularly in higher risk cohorts. (PCa) at diagnosis are at risk for upgrading or upstaging on radical prostatectomy (RP). The possibility of occult aggressive disease is a concern for active surveillance (AS). Accordingly, AS is commonly restricted to men with 3 or fewer positive cores. The goal of this study was to model the relationship between the number of positive cores and the risk of adverse pathology in order to determine a threshold number of cores for AS.
Source of
METHODS: We identified a cohort of 1,820 men who underwent RP at Memorial Sloan Kettering Cancer Center (MSKCC) between January 2000 and August 2016, and had low risk PCa. A comparable cohort of 1,469 French patients treated between December 2004 and November 2012 was identified. Adverse pathology was defined as Gleason score 4+3, seminal vesicle invasion or lymph node involvement. The association between number of biopsy cores and the risk of adverse pathology was analyzed using locally weighted scatterplot smoothing.
RESULTS: In the MSKCC cohort, 171 (9.4%) patients had adverse pathology at RP, compared to 48 (3.3%) in the French cohort. There was a small increase in the risk of adverse pathology with the number of positive cores: patients with 1 positive core had a 4% risk which increased to 8% for patients with 12 positive cores. The increase in risk was smooth, with no discontinuities suggesting an obvious threshold for AS eligibility (Figure 1 ). There were some differences between cohorts, with the change in risk with increasing cores being flatter in MSKCC cohort. However, even in the French cohort, there were not large differences in risk by number of cores.
CONCLUSIONS: There is no number of positive cores threshold associated with a sharp increase in the risk of adverse pathology. Consequently, patients should not be excluded from AS solely based on the number of positive cores. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1191
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